Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

Inclusion Criteria: * Confirmed clinical diagnosis of a Primary Immunodeficiency Disease * Male or female, ages 2 to 70 years * Received 300-900 mg/kg of a licensed IVIG therapy at 21 or 28 day intervals for at least 3 months prior to this study * 2 documented IgG trough levels of ≥ 5 g/L are obtained at two infusion cycles (21 or 28 days) within 12 months (one must be within 6 months) prior to study enrolment * Non-pregnant females of child-bearing potential who agree to use adequate birth control during the study * Subject is willing to comply with the protocol * Authorization to access personal health information. * Signed the informed consent form and a child assent form, if appropriate. * If currently participating in a clinical trial with another experimental IVIG may be enrolled if they have received stable IVIG therapy for at least 3 infusion cycles prior to receiving Kedrion IVIG 10% and all inclusion and exclusion criteria are satisfied * If currently participating in a trial of SCIG can be enrolled if they are switched to IVIG for three infusion cycles (21 or 28 days) prior to enrolment in this study Exclusion Criteria: * Has secondary immunodeficiency. * Newly diagnosed and has not been treated with immunoglobulin or has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency. * Has a history of repeated reactions or hypersensitivity to IVIG or other injectable forms of IgG. * Has a history of thrombotic events defined by at least 1 event i…